Last reviewed · How we verify

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

NCT05832073 EARLY_PHASE1 UNKNOWN

rabies mab CBB 1 is mainly used for passive immunization of patients bitten or scratched by rabies or other animals carrying rabies virus, this study mainly studies the safety, tolerability, pharmacokinetics, neutralizing antibody activity and immunogenic characteristics of rabies mAb CBB 1 in healthy adults

Details

Lead sponsorChangchun BCHT Biotechnology Co.
PhaseEARLY_PHASE1
StatusUNKNOWN
Enrolment152
Start dateSun Apr 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionTue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

China